Verrica Pharmaceuticals Q4 Earnings Call Highlights

Chief Commercial Officer Chris Chapman, who joined in Q4, said priorities include simplifying product acquisition for patients and physicians and ensuring that once a diagnosis is made, a prescription is written. He reiterated that “watchful waiting” remains the largest competitive alternative in molluscum, though management also said the presence of a competitor (ZELSUVMI, mentioned during Q&A) validates demand for active treatment.Management said the company continues to invest in co-pay assistance to sup ...